Aktie A3EES5 CYCLERION THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cyclerion Therapeutics, Inc.

Aktien

A3EES5

US23255M2044

CYCN

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 17.04.2024 		% 5 Tage % 1. Jan.
3.218 USD +1.20% Intraday Chart für Cyclerion Therapeutics, Inc. +3.81% -3.93%
05.03. Cyclerion Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Cyclerion Therapeutics, Inc. ernennt Regina Graul zur Präsidentin CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cyclerion Therapeutics : Private Placement - Form 8-K
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EES5 Aktie
  4. Nachrichten Cyclerion Therapeutics, Inc.
  5. Andere Sprachen